We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Intendis GmbH has started operations as a new, fully integrated pharmaceutical
company, dedicated to the development and marketing of systemic and topical
treatments for skin disorders.
Pharmaceutical company Novartis AG (NVS) has said it will launch a new share-buyback
program valued at up to CHF4 billion, but stressed that it will maintain strategic
flexibility despite the cash outflow.
Novavax, a specialty pharmaceutical company, has received a three-year contract
from NIH to develop a Severe Acute Respiratory Syndrome (SARS) vaccine using
its proprietary Virus Like Particle (VLP) technology.
Basilea Pharmaceutica AG has entered into an exclusive worldwide agreement with
Cilag AG International, a Johnson & Johnson company, to develop, manufacture
and market ceftobiprole, Basilea's novel broad-spectrum cephalosporin antibiotic
that has activity against methicillin-resistant Staphylococcus aureus (MRSA).
Staff at Schering-Plough, which is based at Brinny near Innishannon in West
Cork, were recently told by management that the workforce at the plant is to
be reduced from around 700 to 545 over the next three months.
There is no way Merck will have to declare bankruptcy over pending Vioxx litigation,
nor is it considering a major merger, the company's chief declared.
Biolex, a privately held protein therapeutics company,
has announced the signing of a new agreement with Medarex, an antibody therapeutics
company, to create a commercial line for an undisclosed Medarex monoclonal antibody
using the Biolex LEX System.
A bipartisan bill proposing sales restrictions on certain cold medicines commonly
used to produce methamphetamine is gaining steam in the Senate, much to the
chagrin of advocacy organizations that contend the proposal would limit consumer
access to popular cold treatments such as Sudafed and Tylenol flu medicine.
Two prominent Democratic senators have announced FDA reform plans -- one calling
for the government to require certain postmarketing studies on drug products,
and another proposing the creation of a new drug safety watchdog office under
the auspices of the FDA commissioner.